Cargando…

Surveillance following breast cancer: is it cost-effective?

Detalles Bibliográficos
Autores principales: Ternent, L, MacLennan, G, Heys, SD, Gilbert, F, Vale, L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978822/
http://dx.doi.org/10.1186/bcr2658
_version_ 1782191298975891456
author Ternent, L
MacLennan, G
Heys, SD
Gilbert, F
Vale, L
author_facet Ternent, L
MacLennan, G
Heys, SD
Gilbert, F
Vale, L
author_sort Ternent, L
collection PubMed
description
format Text
id pubmed-2978822
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29788222010-11-13 Surveillance following breast cancer: is it cost-effective? Ternent, L MacLennan, G Heys, SD Gilbert, F Vale, L Breast Cancer Res Poster Presentation BioMed Central 2010 2010-10-25 /pmc/articles/PMC2978822/ http://dx.doi.org/10.1186/bcr2658 Text en Copyright ©2010 Ternent et al; licensee BioMed Central Ltd.
spellingShingle Poster Presentation
Ternent, L
MacLennan, G
Heys, SD
Gilbert, F
Vale, L
Surveillance following breast cancer: is it cost-effective?
title Surveillance following breast cancer: is it cost-effective?
title_full Surveillance following breast cancer: is it cost-effective?
title_fullStr Surveillance following breast cancer: is it cost-effective?
title_full_unstemmed Surveillance following breast cancer: is it cost-effective?
title_short Surveillance following breast cancer: is it cost-effective?
title_sort surveillance following breast cancer: is it cost-effective?
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978822/
http://dx.doi.org/10.1186/bcr2658
work_keys_str_mv AT ternentl surveillancefollowingbreastcancerisitcosteffective
AT maclennang surveillancefollowingbreastcancerisitcosteffective
AT heyssd surveillancefollowingbreastcancerisitcosteffective
AT gilbertf surveillancefollowingbreastcancerisitcosteffective
AT valel surveillancefollowingbreastcancerisitcosteffective